Septerna, Inc. Common Stock Total Liabilities
Septerna, Inc. Common Stock total liabilities. Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has total liabilities worth $191.23 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Septerna, Inc. Common Stock (SEPN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Septerna, Inc. Common Stock (2022–2025)
Total liabilities of Septerna, Inc. Common Stock from 2022 to 2025. This chart illustrates how Septerna, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore Septerna, Inc. Common Stock (SEPN) investment intensity to see how much of total assets are deployed in long-term investments.
Septerna, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Septerna, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atul Limited
NSE:ATUL
|
India | Rs-62.97 Billion |
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
Israel | ILA1.82 Billion |
|
Anhui Xinhua Media Co Ltd
SHG:601801
|
China | CN¥7.53 Billion |
|
Mineros SA
TO:MSA
|
Canada | CA$237.40 Million |
|
Jiangxi Hongcheng Waterworks Co Ltd
SHG:600461
|
China | CN¥14.11 Billion |
|
Bank First National Corp
NASDAQ:BFC
|
USA | $5.13 Billion |
|
Clover Health Investments Corp
NASDAQ:CLOV
|
USA | $358.30 Million |
|
Global Net Lease, Inc.
NYSE:GNL
|
USA | $2.56 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Septerna, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Septerna, Inc. Common Stock asset portfolio.
Liquidity & Leverage Metrics
Septerna, Inc. Common Stock Total Liabilities Ratios Explained
Septerna, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Septerna, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Septerna, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Septerna, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $214.26 Million | +486.90% |
| 2024-12-31 | $36.51 Million | -78.43% |
| 2023-12-31 | $169.24 Million | +110.71% |
| 2022-12-31 | $80.32 Million | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more